AINewsBreaks – Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Collaborates with Resilience Biosciences on AI-Driven Drug Discovery
This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced a collaboration with Resilience Biosciences Inc. to support the development and evaluation of AI-assisted computational chemistry workflows for small-molecule drug development, with the goal of improving efficiency in identifying, analyzing and advancing potential drug candidates. The collaboration will apply Redwood’s computational chemistry, cheminformatics and synthetic route design capabilities to support Resilience’s non-opioid therapeutic development programs, including workflows for derivative generation, patentability and freedom-to-operate analysis, and retrosynthetic planning aimed at accelerating early-stage drug discovery and development. To view the full press release, visit https://ibn.fm/xCQEe About Redwood AI Corp. Redwood…